ERBB2 and breast cancer: On the other hand, an attempt to apply an ML model to predict the pathologic complete response (pCR) to neoadjuvant therapy in HER2+ BC patients based on a subset of clinical features only has demonstrated that clinical features alone are inadequate for defining a useful support system in clinical pathways [124].